文献速递炎症性肠病

接受炎症性肠病生物制剂治疗的女性母乳中药物暴露浓度及母乳喂养对婴儿感染与发育的影响

Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
PubMed 文献 · Gastroenterology · 2018-05-30

多中心前瞻性研究显示,接受英夫利西单抗、阿达木单抗、赛妥珠单抗、那他珠单抗和乌司奴单抗治疗的炎症性肠病女性母乳中可检测到低浓度药物。母乳喂养与非母乳喂养婴儿在12月龄时感染率和发育里程碑评分相似,母亲使用生物制剂、免疫调节剂或联合治疗与未暴露婴儿相比感染和发育里程碑无差异。

要点

  • 接受生物制剂治疗的IBD女性母乳中可检测到低浓度英夫利西单抗、阿达木单抗、赛妥珠单抗、那他珠单抗和乌司奴单抗。
  • 母乳喂养与非母乳喂养婴儿12月龄时感染率(39% vs 39%,P > .99)和里程碑评分(87 vs 86,P = .9992)相似。
  • 母亲使用生物制剂、免疫调节剂或联合治疗与未暴露婴儿相比感染和发育里程碑无差异。

核心结论

  • 接受IBD治疗的女性母乳中可检测到英夫利西单抗、阿达木单抗、赛妥珠单抗、那他珠单抗和乌司奴单抗的低浓度。
  • 母亲使用生物制剂、免疫调节剂或联合治疗所生的母乳喂养婴儿与非母乳喂养或未暴露婴儿相比,感染风险和里程碑达标率相似。
  • 母亲使用生物制剂治疗似乎与母乳喂养兼容。

研究设计与样本

  • 多中心前瞻性研究,纳入IBD女性及其婴儿,2013年10月至2015年11月收集接受生物制剂治疗患者的母乳样本72份。
  • 通过Ages and Stages Questionnaire 3评估儿童发育,824名IBD女性(治疗或未治疗)在孕期完成问卷,其中620名母乳喂养,204名未母乳喂养。
  • 从母亲和儿科医生处获取儿童健康与发育数据,以及母亲用药暴露、IBD病史、活动度、妊娠和产后并发症信息。
  • 使用卡方检验或Fisher精确检验确定分类变量间的关联,使用方差分析模型比较组间连续结局差异。
  • 主要结局为72名女性母乳中生物制剂在给药后1、12、24、48小时的药物浓度,以及可获取样本在72、96、120、168小时的浓度;次要结局为所有母乳喂养婴儿的感染和ASQ-3定义的发育迟缓。

主要发现

  • 29名接受英夫利西单抗治疗的女性中19名母乳样本可检测到药物(最大浓度0.74 μg/mL)。
  • 21名接受阿达木单抗治疗的女性中2名可检测到药物(最大浓度0.71 μg/mL)。
  • 13名接受赛妥珠单抗治疗的女性中3名可检测到药物(最大浓度0.29 μg/mL)。
  • 2名接受那他珠单抗治疗的女性中1名可检测到药物(最大浓度0.46 μg/mL);6名接受乌司奴单抗治疗的女性中4名可检测到药物(最大浓度1.57 μg/mL)。
  • 1名接受戈利木单抗治疗的女性母乳中未检测到药物;母乳喂养与非母乳喂养婴儿12月龄时任何感染率39% vs 39%(P > .99),里程碑评分87 vs 86(P = .9992)。

关键数值与推荐

  • 母乳中英夫利西单抗最大浓度0.74 μg/mL,阿达木单抗最大浓度0.71 μg/mL,赛妥珠单抗最大浓度0.29 μg/mL,那他珠单抗最大浓度0.46 μg/mL,乌司奴单抗最大浓度1.57 μg/mL。
  • 母乳喂养与非母乳喂养婴儿12月龄任何感染率39% vs 39%(P > .99),里程碑评分87 vs 86(P = .9992)。
  • 母亲接受生物制剂、免疫调节剂或联合治疗的婴儿与未暴露婴儿(母亲接受美沙拉秦或类固醇或无用药)相比,感染率和发育里程碑无差异。

临床怎么用

  • 母亲使用生物制剂治疗似乎与母乳喂养兼容。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Exposure to biologic and immunosuppressant agents during breastfeeding is controversial, and there are limited data on safety. We investigated whether biologics are detectable in breast milk from women receiving treatment for inflammatory bowel diseases (IBDs) and whether breastfeeding while receiving treatment is associated with infections or developmental delays. METHODS: We performed a multicenter prospective study of women with IBD and their infants, collecting breast milk samples (n = 72) from patients receiving biologic therapy from October 2013 to November 2015. Drug concentrations were measured in all breast milk samples at several time points within 48 hours of collection and within 168 hours for some samples. Child development was assessed using the Ages and Stages Questionnaire 3, completed by 824 women with IBD (treated or untreated) during pregnancy (620 breastfed, and 204 did not). Data on children's health and development were obtained from mothers and pediatricians, along with information on mothers' medication exposure, IBD history, activity, pregnancy, and postpartum complications. We used chi-squared method or Fisher exact test to determine associations between categorical values and compared differences in continuous outcomes between groups using analysis of variance models. The primary outcome was drug concentration of biologic agents in breast milk (from 72 women) at 1, 12, 24, and 48 hours after dosing and also at 72, 96, 120, and 168 hours for available samples. Secondary outcomes were a range of infant infections and Ages and Stages Questionnaire 3-defined developmental delays among all breastfed infants. RESULTS: We detected infliximab in breast milk samples from 19 of 29 treated women (maximum, 0.74 μg/mL), adalimumab in 2 of 21 treated women (maximum, 0.71 μg/mL), certolizumab in 3 of 13 treated women (maximum, 0.29 μg/mL), natalizumab in 1 of 2 treated women (maximum, 0.46 μg/mL), and ustekinumab in 4 of 6 treated women (maximum, 1.57 μg/mL); we did not detect golimumab in breast milk from the 1 woman receiving this drug. Rates of infection and developmental milestones at 12 months were similar in breastfed vs non-breastfed infants: any infection, 39% vs 39% in control individuals (P > .99) and milestone score, 87 vs 86 in control individuals (P = .9992). Rates of infection and developmental milestones did not differ among infants whose mothers received treatment with biologics, immunomodulators, or combination therapy compared with unexposed infants (whose mothers received treatment with mesalamines or steroids or no medication). CONCLUSIONS: In a study of women receiving treatment for IBD and their infants, we detected low concentrations of infliximab, adalimumab, certolizumab, natalizumab, and ustekinumab in breast milk samples. We found breastfed infants of mothers on biologics, immunomodulators, or combination therapies to have similar risks of infection and rates of milestone achievement compared with non-breastfed infants or infants unexposed to these drugs. Maternal use of biologic therapy appears compatible with breastfeeding. Clinicaltrials.gov no.: NCT00904878.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Matro R, Martin CF, Wolf D, et al. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018. PMID: 29857090. doi:10.1053/j.gastro.2018.05.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。